Neumora Therapeutics reports Q4 and FY financial results and clinical program updates
Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biotechnology company pioneering precision medicines for brain diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025.










